Showing results (21-30 of 33) with videos related to
Sort By:
Pageof 4
Journal of Strength and Conditioning Research|October 27, 2010
The effects of load and training pattern on acute neuromuscular responses in the upper bodyDaniel W Robbins, Tyler L Goodale, David Docherty, et al.The Journal of Organic Chemistry|July 4, 2015
Effects of Molecular Oxygen, Solvent, and Light on Iridium-Photoredox/Nickel Dual-Catalyzed Cross-Coupling ReactionsMartins S Oderinde, Adrian Varela-Alvarez, Brian Aquila, et al.Journal of Strength and Conditioning Research|September 22, 2017
Volume Load and Neuromuscular Fatigue During an Acute Bout of Agonist-Antagonist Paired-Set vs. Traditional-Set TrainingGabriel A Paz, Daniel W Robbins, Carlos G de Oliveira, et al.Journal of Strength and Conditioning Research|May 5, 2010
Physical performance and electromyographic responses to an acute bout of paired set strength training versus traditional strength trainingDaniel W Robbins, Warren B Young, David G Behm, et al.Angewandte Chemie (International Ed. in English)|June 9, 2016
Practical and Broadly Applicable Catalytic Enantioselective Additions of Allyl-B(pin) Compounds to Ketones and α-KetoestersDaniel W Robbins, KyungA Lee, Daniel L Silverio, et al.Nature Chemistry|July 22, 2016
Catalytic enantioselective addition of organoboron reagents to fluoroketones controlled by electrostatic interactionsKyungA Lee, Daniel L Silverio, Sebastian Torker, et al.Angewandte Chemie (International Ed. in English)|July 21, 2016
Highly Chemoselective Iridium Photoredox and Nickel Catalysis for the Cross-Coupling of Primary Aryl Amines with Aryl HalidesMartins S Oderinde, Natalie H Jones, Antoine Juneau, et al.Blood|November 14, 2022
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenograftsDeyi Zhang, Hailey M Harris, Jonathan Chen, et al.Chemmedchem|December 22, 2017
Structure-Based Design of Selective Noncovalent CDK12 InhibitorsJeffrey W Johannes, Christopher R Denz, Nancy Su, et al.Journal of Medicinal Chemistry|February 1, 2024
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton's Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell MalignanciesDaniel W Robbins, Mark A Noviski, Ying Siow Tan, et al.Pageof 4